hdv-insulin lispro + insulin degludec

HDV-insulin lispro + insulin degludec is a combination therapy under investigation for the treatment of type 1 diabetes. It consists of HDV-insulin lispro, where "HDV" stands for hepatocyte-directed vesicle, a technology designed to deliver insulin preferentially to the liver, combined with basal insulin degludec. The rationale is that targeting prandial (mealtime) insulin action to the liver may improve glycemic control and reduce hypoglycemia compared to conventional subcutaneous bolus insulins. Insulin lispro is a rapid-acting human insulin analog, while insulin degludec is an ultra-long-acting basal human insulin analog. The combination aims to optimize both postprandial and basal glucose control in adults with type 1 diabetes who use multiple daily injections[1][4][5][8]. Clinical trials have shown that HDV-lispro can reduce time spent in hypoglycemia without compromising HbA1c reduction when used alongside basal insulins like degludec[8].

Other names

hepatocyte-directed vesicle-insulin lispro + insulin degludec